Kiniksa Pharmaceuticals risk analysis
Want to see KNSA full AI Analyst Report?
Kiniksa Pharmaceuticals (KNSA) Risk Analysis
Risk Overview Q2, 2026
Source: the company's latest filing for the period ended Jun 30, 2026, filed Jul 28, 2026
Risk Change Over Time
- Share Price & Shareholder Rights - Risk 1Item 5. Other Information. Trading Arrangements
During the fiscal quarter ended June 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" as such terms are defined under Item 408 of Regulation S-K.
- Share Price & Shareholder Rights - Risk 2Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities
None.
- Debt & Financing - Risk 3Item 3. Defaults Upon Senior Securities.
None.
Risk Highlights Q2, 2026
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 66
- Innovation / R&D - Risk 1We are conducting a technology transfer with respect to the manufacturing process of ARCALYST drug substance from Regeneron to Samsung and the analytical testing methods of ARCALYST drug substance and drug product to new CTLs. Such technology transfer will be subject to significant risks and uncertainties.
In March 2023, Regeneron, our sole supplier of ARCALYST drug substance, initiated a technology transfer related to the manufacturing process of ARCALYST drug substance and the analytical testing methods of ARCALYST drug substance and drug product. Since then, we have worked to qualify Samsung as the new manufacturer of ARCALYST drug substance, and new CTLs who will serve as the new testing labs of ARCALYST drug substance and drug product. We have also contracted with Samsung to document the technology transfer and enable commercial manufacturing, if successful. Pharmaceutical development, manufacture and analytical testing requires significant expertise and capital investment, and the manufacture and testing of biologics, in particular, can be complex and difficult. While we have selected Samsung as our replacement CDMO and have selected replacement CTLs, we are still in the technology transfer process, which is a time-consuming and difficult task that may require significant time and focus from our management and technical teams. Further, because of the complexities of this process, the technology transfer may be subject to substantial delay. We have yet to receive final regulatory approval to proceed. Such final approval may be substantially delayed due to the complexity of the technology transfer and related processes, an inability to successfully complete validating Samsung as a CDMO and our new CTLs, disruptions at the FDA and other factors. Such a delay could materially harm our business and operations. In addition to the need to successfully complete the technology transfer of ARCALYST drug substance manufacturing to Samsung, the facility at which Samsung will manufacture ARCALYST will require approval by the FDA prior to the sale of ARCALYST manufactured at such facility. The FDA generally requires that any replacement CDMO be able to manufacture drug substance at sufficient levels of comparability with the materials produced by the original manufacturer. Failure to provide sufficient evidence of comparability may result in the FDA requesting a bioequivalence or pharmacokinetic study, which would delay our expected technology transfer timeline. We cannot guarantee that the FDA will approve the Samsung facility. Further, because the Samsung manufacturing facility is located in South Korea, unlike Regeneron's United States-based manufacturing facility, we may face new risks arising from tariffs, import/export restrictions, customs proceedings, product being lost or damaged during international shipping, differing regulations, supply chain interruptions and other risks inherent to international operations. These risks, should they occur, could increase our costs and affect our ability to meet clinical and commercial demand for ARCALYST, which could materially impact our business, financial condition and results of operations. Regeneron is contractually obligated to continue manufacturing ARCALYST drug substance for at least a portion of the time that it will take us to qualify Samsung as a replacement CDMO. During such time, Regeneron will remain subject to many of the risks described elsewhere in this "Risk Factors" section, including the risk that it is unable to manufacture sufficient quantities of ARCALYST and at sufficient quality to meet ours and our patients' and collaborators' needs. Further, because we expect the timeline for any successful technology transfer to extend beyond Regeneron's contractual obligations, meeting patient demand will depend significantly on securing sufficient safety stock from Regeneron, negotiating continued ARCALYST drug substance manufacture by Regeneron beyond its contractual obligations or some combination thereof. Purchasing safety stock requires significant upfront investment and such stock may expire or run out before completion of the technology transfer. Regeneron may also disagree with our forecasted safety stock requirements and manufacture less ARCALYST drug substance than we request, exposing us to risks if the technology transfer process is significantly delayed. Any arrangement that we negotiate with Regeneron to manufacture ARCALYST beyond their contractual obligations may not be on as favorable terms as our current relationship, which could materially increase our costs. A failure to secure sufficient safety stock or negotiate satisfactory manufacturing terms with Regeneron could result in supply shortages for our patients and collaborators while we work to complete the technology transfer. A failure to either complete our planned technology transfer on our expected timeline or at an acceptable cost and/or secure sufficient supply of ARCALYST through the technology transfer process would have a material impact on our business, financial condition and results of operations.
- Innovation / R&D - Risk 2Interim, preliminary and "top-line" data from our clinical trials may differ from final data.
From time to time we may announce or publish interim, topline or preliminary data from our preclinical studies or clinical trials, which are based on an interim or preliminary analysis of the then available data from an in-progress or completed study, as applicable. Such data may be subject to change following a more comprehensive review of the data from the particular clinical trial. Interim data may change, and such change may be material, as participant enrollment continues or patients continue on treatment in the study. For preliminary or topline data, we also make assumptions, estimations, calculations and conclusions as part of our preliminary analyses, and, as a result, such data remain subject to audit and verification procedures that may result in the final data being different from the data we previously announced or published. Interim data should be viewed with caution until final data are available. Third parties, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our business prospects. In addition, the information we announce or publish regarding a particular preclinical study or clinical trial may represent only a portion of extensive information generated from that study or trial, and our shareholders or other third parties may not agree with what we determine is material, important or otherwise appropriate information to include in our disclosure. If the interim, preliminary or topline data that we report differ materially from final results, or if third parties, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business prospects, operating results or financial condition. Further, announcement of preliminary, interim or top-line data by us or differences between that data and the final data could result in volatility in the price of our Class A ordinary shares.
- Innovation / R&D - Risk 3Undesirable side effects or adverse reactions caused by any of our product candidates may be identified that could delay or prevent their marketing approval or limit their use.
Undesirable side effects or adverse reactions caused by our product candidates could cause our CROs, an IRB or regulatory authorities to interrupt, delay or halt an ongoing clinical trial and could result in the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. Even if approved, such events could lead to restrictions to the product's label that could materially limit our ability to successfully commercialize the product. For example, many of our assets modulate the immune system and carry risks associated with immunosuppression, such as serious infections or malignancy. In addition, if other molecules in the same or related class being developed or commercialized by third parties show the same or similar side effects as those we observed in our trials but to a greater degree or report new previously-unreported side effects, it could have an impact on the entire class of molecules, and the applicable regulatory authority may modify, suspend, or terminate our clinical trials; not authorize further clinical trials; require post-marketing clinical trial commitments or safety monitoring (e.g., REMS); or even suspend commercialization of any products or product candidates, as applicable, that contain a molecule within such class. The development of our product candidates and, if approved, commercialization of our products for new indications or new patient populations by Regeneron or Huadong (each having certain rights to develop and commercialize ARCALYST) may increase the possibility of uncovering adverse safety results not previously discovered during our own clinical development process or United States commercialization. Compassionate use of our products and product candidates, or evaluation of our products and product candidates by third parties or scientific collaborations could also uncover undesirable side effects or adverse safety results that negatively impact our clinical trials. If any of our product candidates is associated with undesirable side effects or adverse reactions, we may choose to halt or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or adverse reactions are less prevalent, less severe or more acceptable from a risk-benefit perspective. In addition, clinical trials by their nature utilize a sample of the potential patient population. However, with a limited number of participants and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered when a significantly larger number of patients are exposed to the product. If we or others later identify undesirable side effects caused by our products or product candidates, if approved, a number of potentially significant negative consequences could result, including but not limited to: - regulatory authorities may withdraw approvals of such product and require us to take it off the market;- regulatory authorities may require the addition of labeling statements, specific warnings, contraindications or field alerts to prescribers and pharmacies;- we may be required to create a registry or a REMS or similar risk management measures;- we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product; and - we may be subject to limitations on how we promote the product. Any of these events could prevent us from achieving or maintaining market acceptance of the particular product or product candidate, and could significantly harm our business, results of operations and prospects.
- Innovation / R&D - Risk 4We may find it difficult to enroll participants in our clinical trials in a timely manner given the limited number of patients who have the diseases for which our product candidates are being studied, our particular enrollment criteria or competing clinical studies in the same patient population.
The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion, particularly given that many of the conditions for which we are evaluating our current product candidates or may evaluate in the future are in small disease populations. Accordingly, when we encounter difficulties in enrollment, we have experienced and may in the future experience delays, or we may be prevented from completing our clinical trials. Participant enrollment depends on many factors, including: - the size and nature of the patient population;- the severity of the disease being studied;- participant referral practices of prescribers;- participant eligibility criteria for the clinical trial and evolving standards of care;- the proximity of participants to clinical sites;- the complexity of the design and nature of the clinical protocol and trial;- the fact that our product candidates modulate the immune system and carry unique risks associated with immunosuppression, including the risk of serious infections, potential interference with vaccines and other potential serious health risks;- the availability and nature of competing clinical trials;- the availability of standard of care and/or new or existing drugs approved for the indication we are investigating;- failure to obtain, maintain and/or timely amend participant consents;- our ability to recruit clinical trial investigators with applicable competencies and experience;- participants withdrawing from trials before completing their treatment or follow-up period;- clinicians' and participants' perceptions as to the safety and potential advantages of the product candidate being studied in relation to other available therapies; and - the occurrence of adverse events or undesirable side effects attributable to our product candidates. The process of finding and enrolling participants may prove costly, especially since we are looking to identify a subset of the participants eligible for our studies from a relatively small patient population for many of the diseases we are studying. Encountering difficulties in participant enrollment could cause our costs to significantly increase, and our clinical trials may be significantly delayed. Such occurrences may also delay or prevent any potential regulatory approval and commercialization, harming our business, financial condition and prospects significantly.
- Innovation / R&D - Risk 5Clinical drug development is a lengthy and expensive process with uncertain timelines and outcomes. We may encounter substantial delays in our clinical trials, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. We may therefore be unable to obtain required regulatory approvals and be unable to successfully commercialize our product candidates on a timely basis, if at all.
Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Commencing a clinical trial is subject to acceptance by the FDA of an IND or IND amendments, acceptance by competent authorities of the EU member states of a CTA under the CTR or acceptance by other applicable regulatory authorities. Clinical testing is expensive, time consuming and uncertain as to the outcome. See "Business – Government Regulation" for more information on the regulations governing our clinical trials and product development. Not all of our clinical trials have been conducted as initially planned or completed on our initial projected schedule, and, accordingly, we cannot guarantee that any of our current or future clinical trials will be conducted as initially planned or completed on our initial projected schedule, if at all. Further, even if conducted on time, a clinical trial may result in unfavorable or statistically insignificant results, leading us to abandon our pursuit of a particular indication or the development of a product candidate entirely. Clinical trials are a lengthy process that require the expenditure of significant money and human capital. Failing to achieve desired efficacy or identifying of a novel safety hazard in turn represents an inability to successfully recoup such expense via a potential commercialization of the product candidate, if approved. A failure of one or more of our current or future clinical trials can occur at any stage of testing, and our clinical trials may not be successful. We have experienced and may continue to experience delays in our ongoing clinical trials, and we do not know whether planned clinical trials will begin on time, be allowed by regulatory authorities, require redesign, have timely site activation and participant enrollment or be completed on schedule, if at all. Factors that have and may in the future delay or prevent commencement or successful completion of clinical development of our product candidates as planned and on schedule, if at all, include but are not limited to: - insufficient preclinical, toxicology or other data to support initiation of human trials;- disagreements with regulatory agencies regarding trial design or implementation, including the appropriate dose levels, frequency of dosing, treatment period or endpoints in clinical trials;- delays or failure in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;- difficulties obtaining IRB or ethics committee approval at each clinical trial site;- delays or failure in obtaining regulatory approval to commence a clinical trial or the imposition of a clinical hold by regulators;- difficulties in enrolling suitable participants due to competition from other clinical trials in the particular indication;- clinical trial protocol amendments impacting study criteria, endpoints or design, including amendments that either we initiate or are requested by regulatory authorities;- difficulty collaborating with patient groups and/or investigators;- CROs, clinical trial sites or applicable third parties failing to adhere to clinical trial requirements or comply with applicable law;- CROs, clinical trial sites or applicable third parties failing to conform to GCPs;- participants not completing a clinical trial or not returning for post-treatment follow-up;- clinical trial sites withdrawing from a trial or being unable to conduct activities or participants withdrawing from clinical trials;- participants experiencing serious adverse events, undesirable side effects or unacceptable health risks;- participants failing to experience confirmed pre-specified events during the clinical trial within the expected timeframe, if at all;- safety concerns outweighing potential benefits;- regulatory changes requiring protocol amendments or new submissions;- failure by us, our CROs or other third parties with whom we contract to timely and properly collect, analyze and/or assess clinical data;- higher than expected clinical trial or clinical product manufacturing costs;- strategic clinical trial reprioritization;- errors in collecting, analyzing and assessing clinical data;- clinical trials producing negative, inconclusive or uncompetitive results;- failures to replicate safety, efficacy or other data from earlier preclinical studies and clinical trials conducted by us or third parties, including the trials of companies from whom we have licensed or acquired assets;- the occurrence of unforeseen adverse events;- trial suspensions or terminations by us, IRBs, DSMBs, DMCs, or regulators;- insufficient production of product candidates meeting cGMP standards;- manufacturing or supply chain delays; and - operational disruptions affecting us, our CROs or our CDMOs and other third parties we rely on to conduct our clinical trials. Delays in the commencement or completion of our clinical trials have occurred and may occur in the future. Consequences of delays have increased and may in the future increase our costs of developing our product candidates, delay the development and approval of our product candidates or delay or jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, difficulties and delays in the commencement or completion of clinical trials may also lead to the denial of regulatory approval of our product candidates or us deciding to modify or cease development of our product candidates. Clinical trial delays could also shorten any periods during which we have patent protection or have the exclusive right to commercialize our product candidates, and may allow our competitors to bring products to market before we do, which could impair our ability to obtain orphan exclusivity for our products that potentially qualify for this designation and to successfully commercialize our product candidates. Clinical trials must be conducted in accordance with a number of national and international rules and regulations in the jurisdictions where such clinical trials are conducted. See "Business – Government Regulations". Further, conducting global clinical trials, as we do for certain of our product candidates, requires that we coordinate among the legal requirements and guidelines of regulatory authorities across a number of jurisdictions, including the United States, the EU, the UK and countries outside of those jurisdictions, which could require that we amend clinical trial protocols, terminate a trial in one or more jurisdictions or run separate trials in various jurisdictions due to the inability, cost or delay in harmonizing divergent requests from such regulatory authorities, all of which could increase costs. In addition, clinical trials that are conducted in countries outside the United States, the EU and the UK may subject us to risks associated with the engagement of CROs who are unknown to the FDA, the EMA or the EU national component authorities or the MHRA and may have different standards of diagnosis, screening and medical care. Such trial sites may also incur risks associated with further delays and expenses as a result of increased shipment costs (including as a result of local quality release or in-country testing of a product candidate supply produced in a different jurisdiction for our clinical trials) and political and economic risks relevant to such countries outside the United States, the EU and the UK. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. In addition, clinical trial rules and regulations may change. Such changes may require us to dedicate time, resources and capital to comply and, if we are unable to do so effectively or on a timely basis, our development plans may be impacted and our business may suffer material harm.
- Innovation / R&D - Risk 6If we are unable to advance our product candidates in clinical development and obtain regulatory approval, or experience significant delays in doing so, our business may be significantly harmed.
Our product candidates are in various stages of clinical development. We base our projections about the future development and potential approval of our product candidates on indirect data from other companies and the results of our preclinical and clinical trials, but ultimate success is uncertain and involves significant risk. We cannot be certain that any of our product candidates will be successful in their clinical trials or will receive regulatory approval. Further, we may choose to cease development of a product candidate prior to conducting a pivotal trial for any reason, including capital conservation purposes. We may also choose not to commercialize a product candidate that has completed a pivotal trial or received regulatory approval for a number of reasons, including commercial viability. Such decisions may be for a particular indication or for the product candidate entirely. In the event that a product candidate is unsuccessful in its clinical trials, fails to receive regulatory approval, is deprioritized for strategic reasons or is non-viable for another reason, our business may be materially harmed by limiting our ability to recoup our development expenses through a successful commercial launch. Each of our product candidates requires substantial preclinical or clinical development and manufacturing support as part of our product development strategy. The clinical success of our current and future product candidates depends upon several factors, including, but not limited to, the following: - submission to and authorization to proceed with clinical trials by the FDA under INDs and CTAs to applicable authorities outside of the United States;- successful completion of required nonclinical studies, including toxicology studies, pharmacological and biodistribution studies, as conducted, where applicable, under GLP;- successful site activation for, enrollment in and completion of clinical trials, including the ability of our CROs to successfully conduct such trials within our planned budget and timing parameters without adversely impacting our trials, and our ability to successfully oversee CRO activities;- positive data from our clinical programs, including post-marketing trials and those intended to satisfy regulatory commitments or for label expansion, with sufficient quality to support an acceptable risk-benefit profile of our products and product candidates for the targeted indications in the intended populations to the satisfaction of the applicable regulatory authorities;- timely receipt, if at all, of approvals from applicable regulatory authorities and maintenance of any such approvals;- as applicable, acceptance of pediatric study plans by regulatory authorities, and the follow through of any pediatric study commitments, such as development of pediatric formulations, if required;- successful manufacture of sufficient supply of our product candidates within approved specifications for purity, efficacy and cGMP requirements from our facility and from our CDMOs or other sole-source manufacturers in order to meet clinical or commercial demand, as applicable, for ourselves and for our partners;- continued compliance with any post-marketing requirements imposed by regulatory authorities, including any required post-marketing clinical trial commitments or REMS or similar risk management measures; and - maintenance of a continued acceptable safety profile of our product candidates before and following approval. If we do not accomplish one or more of these factors in a timely manner or at all we could experience significant delays in, or an inability to, timely or successfully commercialize our product candidates.
- Innovation / R&D - Risk 7We may seek Breakthrough Therapy designation or Fast Track designation by the FDA, for one or more of our product candidates, which we may not receive. Such designation may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval.
We may seek Breakthrough Therapy or Fast Track designation for one or more of our product candidates, which, if granted, offers the potential for a rolling review of a BLA if a number of conditions are met, which would allow data to be submitted and reviewed as they become available rather than waiting for the full data package to become available to be submitted. Rolling review is often faster than the FDA's standard review process. The FDA has broad discretion whether or not to grant Fast Track and Breakthrough Therapy designations, and even if we believe a particular product candidate is eligible for such designations, we cannot be certain that the FDA would decide to grant them. Even if we obtain such designations for one or more of our product candidates, we may not experience a faster development process, review or approval compared to non-expedited FDA review procedures. In addition, the FDA may withdraw Fast Track or Breakthrough Therapy designations if it believes that such designations are no longer supported. Although product candidates receiving Fast Track and Breakthrough Therapy designation are generally eligible for the FDA's priority review procedures, receiving such designations does not guarantee that the BLA for such product candidates will receive priority review. See "Business – Government Regulation" for more information on applicable rules and regulations.
- Innovation / R&D - Risk 8We may seek Orphan Drug designation for our product candidates in the United States, as well as for any of our product candidates in the EU, and we may be unsuccessful, or may be unable to maintain the benefits associated with Orphan Drug designation, including the potential for market exclusivity, for any product candidate for which we obtain Orphan Drug designation.
Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs or biologics intended to treat small patient populations as Orphan Drug products, which are subject to a number of region-specific (e.g., tax credits, user fee exemptions and potential market exclusivity) rules and regulations. See "Business – Government Regulation" for more information on applicable rules and regulations. We have received Orphan Drug exclusivity in the United States for ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older. We have received Orphan Drug designation in the United States for KPL-387 for the treatment of recurrent pericarditis. In addition, we have received Orphan Drug designation in the EU for ARCALYST for the treatment of idiopathic pericarditis. In the future, we may seek Orphan Drug designation for certain of our other product candidates in the United States or the EU. We may be unsuccessful in obtaining such designation for any of our other product candidates or unable to maintain the associated benefits for any of our other current or future product candidates that are granted Orphan Drug designation, if any. Even if we obtain Orphan Drug designation for certain product candidates for a particular orphan indication in the United States or the EU, we may not be the first to obtain marketing approval for such orphan indication due to the uncertainties associated with developing pharmaceutical products. In such cases, subject to applicable laws in those jurisdictions, Orphan Drug exclusivity may no longer be available for our product candidates, if approved, unless we can show a significant safety or efficacy advantage over the already approved orphan drug. Moreover, in the event our drug is deemed similar to the first approved orphan drug, we may be denied regulatory approval for our drug in such orphan indication for the duration of the Orphan Drug exclusivity period. Further, in order to maintain Orphan Drug exclusivity in the EU, we must demonstrate that our product or product candidate has a significant benefit over other satisfactory methods. If we are unable to do so, Orphan Drug exclusivity can be withdrawn. In connection with the FDA's approval of ARCALYST in the recurrent pericarditis indication, we received seven years of Orphan Drug exclusivity for ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older. We may also receive seven years of Orphan Drug exclusivity for KPL-387 in the same indication, should we receive FDA approval to market and commercialize the drug and satisfy the other requirements for such exclusivity. Even if Orphan Drug exclusivity is obtained, that exclusivity may not effectively protect those product candidates from competition because different drugs can be approved for the same disease or condition. Even after an Orphan Drug is approved, the FDA can subsequently approve a later application for the same drug for the same disease or condition if the FDA concludes that the later drug is clinically superior because of safety, efficacy or some other contribution to patient care. In addition, a designated Orphan Drug may not receive Orphan Drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, Orphan Drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Foreign regulatory authorities may also make the same determination. Orphan Drug designation also neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.
- Innovation / R&D - Risk 9We may not be able to continue to commercialize ARCALYST or be successful in commercializing any future products, potentially impairing the commercial potential for our current and future products to generate any revenue.
Since our commercial launch of ARCALYST, we have focused on establishing and expanding our sales, marketing, distribution, access and payor and patient support services capabilities as well as contracting with third parties to perform certain services. Each aspect of commercialization on its own can be complex, expensive and time consuming, and, collectively, the required effort for coordination is intensive. While we have realized revenues from such efforts, there is no guarantee that we will be able to maintain the trajectory of growth or significant and sustained revenues in the future. In addition, our continued commercialization of ARCALYST or successful commercialization of any of our current or future product candidates, if approved, could be materially adversely impacted by a number of foreseen and unforeseen factors, including: - any delays in our ability to produce sufficient quantities of ARCALYST, or any of our future products, at an acceptable cost or quality, including delays arising out of quality assurance concerns or changes in regulatory guidance, or those caused by our reliance on our third party manufacturers;- our inability to recruit, train and retain adequate numbers of effective sales, marketing, access and payor and patient support personnel;- the inability of sales personnel to obtain access to prescribers and accounts;- an inadequate number of prescribers or accounts prescribing our current and future products;- the lack of complementary products to be supported by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;- our inability to equip customer-facing personnel with effective materials, including medical and sales literature to help them educate physicians and other healthcare professionals regarding applicable diseases relevant to ARCALYST or any of our future products;- an absence or reduction in strong scientific-based relationships to drive disease awareness and education;- our inability to establish the unmet medical need for a given disease;- our inability to provide acceptable evidence of safety and efficacy;- the prevalence and severity of side effects associated with any future product;- our inability to compete with current or future competitor products and/or biosimilars;- the convenience and ease of administration of our products relative to alternative therapies, if any;- alternative therapies that use the same or different mechanism of action for treating patients with recurrent pericarditis or other indications that our future products may treat;- our inability or delay in gaining or maintaining reimbursement and broad patient access at a price that reflects the value of ARCALYST or any of our future products;- limitations on the content or form of the consumer and/or prescriber-facing marketing materials that we may use;- any delays in the ongoing technology transfer of the process for manufacturing ARCALYST drug substance;- our inability to provide prescribers and patients adequate support and training to build comfort around the preparation and administration process to initiate and continue to use ARCALYST or any of our future products;- our inability to develop or sustain robust patient support programs to optimize the patient and customer experience with ARCALYST or any of our future products;- publications of scientific literature, consensus papers and treatment guidelines unfavorable to the administration of our products and product candidates and/or the positioning of the class of drugs to which each of our products and product candidates belongs;- our inability to establish and maintain patent and trade secret protection or regulatory exclusivity for our products;- our inability to enforce and defend our intellectual property rights and claims; and - unforeseen costs and expenses associated with creating and maintaining a sales, marketing and access organization. If we experience any such factors that inhibit our efforts to commercialize ARCALYST or any of our product candidates, if approved, our business, results of operations, financial condition and prospects may be materially adversely affected.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.

